Abstract:Butyrate—a metabolite produced by commensal bacteria—has been extensively studied for its immunomodulatory effects on immune cells, including regulatory T cells, macrophages and dendritic cells. However, the development of butyrate as a drug has been hindered by butyrate's poor oral bioavailability, owing to its rapid metabolism in the gut, its low potency (hence, necessitating high dosing), and its foul smell and taste. Here we report that the oral bioavailability of butyrate can be increased by esterifying it to serine, an amino acid transporter that aids the escape of the resulting odourless and tasteless prodrug ( O -butyryl- l -serine, which we named SerBut) from the gut, enhancing its systemic uptake. In mice with collagen-antibody-induced arthritis (a model of rheumatoid arthritis) and with experimental autoimmune encephalomyelitis (a model of multiple sclerosis), we show that SerBut substantially ameliorated disease severity, modulated key immune cell populations systemically and in disease-associated tissues, and reduced inflammatory responses without compromising the global immune response to vaccination. SerBut may become a promising therapeutic for autoimmune and inflammatory diseases.

What problem does this paper attempt to address?

The main issue this paper attempts to address is improving the bioavailability of butyrate as an oral drug and evaluating its effectiveness in treating autoimmune diseases. Specifically, the researchers designed a prodrug (SerBut) that combines butyrate with serine to overcome the problems of rapid metabolism, low efficacy, and unpleasant odor and taste of butyrate in the gut. In this way, the researchers hope to enhance the systemic absorption of butyrate, thereby improving its therapeutic effects in the body. ### Main Research Questions: 1. **Improving the oral bioavailability of butyrate**: By combining butyrate with serine to form a new prodrug (SerBut), the researchers aim to improve the oral bioavailability of butyrate, allowing it to better enter the bloodstream and exert its therapeutic effects. 2. **Evaluating the efficacy of SerBut in autoimmune diseases**: The researchers evaluated the therapeutic effects of SerBut in two mouse models: the collagen antibody-induced arthritis (CAIA) model and the experimental autoimmune encephalomyelitis (EAE) model. These models are used to simulate rheumatoid arthritis and multiple sclerosis, respectively. ### Research Methods: - **Chemical Synthesis**: SerBut was synthesized through chemical methods. - **Biodistribution Study**: The biodistribution and bioavailability of SerBut were evaluated by measuring butyrate levels in plasma and major organs after oral administration. - **Cell Experiments**: The biological activity of SerBut was assessed in RAW 264.7 macrophages and bone marrow-derived dendritic cells (BMDCs), including histone deacetylase (HDAC) inhibitory activity and effects on immune cells. - **Animal Model Experiments**: The therapeutic effects of SerBut were evaluated in CAIA and EAE mouse models, including disease scoring, pathological analysis, and changes in immune cell populations. ### Main Findings: - **Improved Bioavailability**: SerBut significantly increased the levels of butyrate in plasma and multiple organs, especially in the brain and spinal cord. - **Therapeutic Effects**: In the CAIA model, SerBut significantly inhibited the development of arthritis, reduced inflammatory responses, and joint damage. In the EAE model, SerBut prevented the onset of the disease, reduced immune cell infiltration, and upregulated the expression of immunoregulatory molecules. - **Immunoregulatory Mechanism**: SerBut exerted its immunoregulatory effects by increasing the proportion of regulatory T cells (Treg cells), upregulating the expression of PD-1 and CTLA-4, and reducing the number of pro-inflammatory cells (such as TH17 cells). Overall, this study successfully improved the oral bioavailability of butyrate through the design and evaluation of SerBut and demonstrated its potential in treating autoimmune diseases.

A serine-conjugated butyrate prodrug with high oral bioavailability suppresses autoimmune arthritis and neuroinflammation in mice

Injectable butyrate-prodrug micelles induce long-acting immune modulation and prevent autoimmune arthritis in mice

Microbiota-Derived Metabolites Suppress Arthritis by Amplifying Aryl-Hydrocarbon Receptor Activation in Regulatory B Cells

Intestinal butyrate-metabolizing species contribute to autoantibody production and bone erosion in rheumatoid arthritis

A Sustained-Release Butyrate Tablet Suppresses Ex Vivo T Helper Cell Activation of Osteoarthritis Patients in a Double-Blind Placebo-Controlled Randomized Trial

Prevotella histicola Protects From Arthritis by Expansion of Allobaculum and Augmenting Butyrate Production in Humanized Mice

P036 Microbiota Metabolite Butyrate Attenuates Intestinal Inflammation Through Autophagy Activation

Butyrate Alleviates Cognitive Impairment by Improving Gut Mucosal Barrier Function and Blocking Neuroinflammatory Signaling in LDLR-/- Mice

The Potential Role of Butyrate in the Pathogenesis and Treatment of Autoimmune Rheumatic Diseases

Butyrate Prevents the Pathogenic Anemia‐Inflammation Circuit by Facilitating Macrophage Iron Export

Oral administration of sodium butyrate attenuates inflammation and mucosal lesion in experimental acute ulcerative colitis

An orally administered butyrate-releasing xylan derivative reduces inflammation in dextran sulphate sodium-induced murine colitis

Butyrate: a Bridge Between Intestinal Flora and Rheumatoid Arthritis

A tailored series of engineered yeasts for the cell-dependent treatment of inflammatory bowel disease by rational butyrate supplementation

3,3-Dimethyl-1-Butanol and its Metabolite 3,3-Dimethylbutyrate Ameliorate Collagen-induced Arthritis Independent of Choline Trimethylamine Lyase Activity

Treatment of peanut allergy and colitis in mice via the intestinal release of butyrate from polymeric micelles

DOP39 Constructing butyrate-producing yeast as a cell-dependent treatment option for Inflammatory Bowel Disease

BUTYRATE AMELIORATES INFLAMMATION IN COLON BIOPSY SAMPLES OF IBD PATIENTS AND EXPERIMENTAL COLITIS IN MICE INVOLVING RNA BINDING PROTEIN, AUF1-IL-27 AXIS AND ACCELERATING B1a TO B10 POLARIZATION

Butyrate Properties in Immune-Related Diseases: Friend or Foe?

S-Propargyl-Cysteine Remodels the Gut Microbiota to Alleviate Rheumatoid Arthritis by Regulating Bile Acid Metabolism

A Synbiotic Formulation Comprising Bacillus subtilis DSM 32315 and L-Alanyl-L-Glutamine Improves Intestinal Butyrate Levels and Lipid Metabolism in Healthy Humans